BioInvent and ThromboGenics to Regain Full Rights to TB-403

05 Jun 2012

Plan to evaluate the potential of this therapeutic antibody against PIGF in cancer and non-cancer indications, including ophthalmology

Lund, Sweden and Leuven, Belgium - 5 June 2012 - BioInvent International AB (OMXS: BINV) and co-development partner ThromboGenics NV (Euronext Brussels: THR) announce today that they will regain global rights to TB-403 from Roche (SIX: RO, ROG; OTCQX: RHHBY). TB-403 was licensed to Roche in 2008. ThromboGenics and BioInvent plan to further evaluate the potential of TB-403 in certain cancer and non-cancer indications, including ophthalmology. Clinical studies with TB-403 to-date have shown that it is safe and well tolerated. Roche's decision was due to the prioritization of resources in the Roche portfolio.

TB-403 is a monoclonal antibody against placental growth factor (PlGF). PIGF is a naturally occurring protein that belongs to the family of vascular endothelial growth factors (VEGF) that promote the formation of blood vessels. TB-403's ability to block the growth of new blood vessels and modulate inflammation means it could potentially be used in a broad range of cancer and non-cancer indications.

Svein Mathisen, CEO of BioInvent, said: "TB-403's ability to selectively block the formation of new blood vessels provides us with a therapeutic antibody candidate that could have potential in indications where it has so far not been fully assessed. We intend to evaluate such opportunities and will provide an update when data are available."

Dr Patrik De Haes, CEO of ThromboGenics, added: "Regaining all rights to TB-403, an antibody which blocks PIGF, will allow us to evaluate its potential as a treatment for a number of significant retinal diseases including diabetic retinopathy and AMD. We believe that our lead product ocriplasmin will allow us to establish a strong market position in the treatment of retinal disorders where vitreomacular adhesion plays a role. By investing in the development of TB-403 we could have another exciting new product to accelerate the growth of our emerging ophthalmology franchise."Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

To the editors:

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focusing on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences and ThromboGenics.

The company's competitive position is underpinned by its proprietary antibody development platform. The scope and strength of this platform is also utilized by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. More information is available at www.bioinvent.com.

About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company's lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion (VMA)/ Vitreomacular Traction (VMT). The MAA for ocriplasmin has been accepted for review in Europe and the BLA has been re-submitted in the U.S. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. Under this agreement, ThromboGenics could receive up to a total of EUR375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon's net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vitreoretinal indications.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

For further information, please contact:

BioInvent International AB

Svein MathisenÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sten Westerberg
President & CEOÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vice President, Investor Relations
Mobile: +46 (0)708 97 82 13Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Mobile: +46 (0)768 68 50 09
E-mail: [email protected]Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â E-mail: [email protected]

College Hill (media enquiries)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The Trout Group
Melanie Toyne Sewell Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Christine Yang
Phone: +44 (0)20 7866 7856Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vice President
Rebecca Skye DietrichÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Tel: +1Â 646Â 378 2929
Tel: +1 (857)Â 241 0795Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â E-mail: [email protected]
E-mail: [email protected]

ThromboGenics NV

Dr Patrik De HaesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Chris Buyse
CEOÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CFO
Tel: +32 16 75 13 10Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Tel: +32 16 75 13 10
E-mail: [email protected]Â Â Â Â Â Â Â Â Â Â E-mail: [email protected]

Citigate Dewe RogersonÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The Trout Group
David Dible / Nina Enegren / Sita ShahÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Todd james, Director
Tel: +44 20 7638 9571Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Simon Harnest, Associate
E-mail: [email protected]Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Tel: +1Â 646Â 378 2929
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â E-mail: [email protected]

BioInvent International AB (publ)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â ThromboGenics NV
Co. reg. No. 556537-7263,Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Gaston Geenslaan 1
Visiting address: Sölvegatan 41Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â B-3001 Heverlee
Mailing address: SE-223 70 LUNDÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Belgium
Phone: +46 (0)46 286 85 50Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Phone: +32 (0)16 75 13 10
[email protected]Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â www.thrombogenics.com

www.bioinvent.com

Legal disclaimer

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same was as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 7.30 a.m. CET, on 5 June, 2012.